A comparative study of norethisterone and dydrogesterone in the treatment of heavy menstrual bleeding
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20252321Keywords:
Dydrogesterone, HMB, Norethisterone, PBACAbstract
Background: HMB is described as bleeding for >7 days or >80 ml per cycle/ having a higher than 100 score on the pictorial blood assessment chart (PBAC). Medical management is the first line of treatment. Norethisterone is most commonly used oral progestin. Dydrogestrone is a C-21 derivative which is highly selective synthetic progestin, closely related to endogenous progesterone.
Methods: The 170 cases of heavy menstrual bleeding (HMB) with ovulatory disorder in the range of 20-45 years of age were assigned into two groups (85 women in each group). Group A received Norethisterone 10 mg and Group B received Dydrogesterone 10 mg twice daily respectively till bleeding stopped, the same dose was continued for another one week and then 10 mg OD for one week till 28 days of LMP whichever was later. Both the groups were followed up for another 3 cycles and response to treatment were analysed using PBAC score and Hb levels before and after treatment.
Results: A significant decrease in PBAC score and improvement in haemoglobin level were observed in both the groups i.e. 82.35% women in Norethisterone group and 78.82% in Dydrogesterone group respectively. In Norethisterone group 3.53% and 7.08% women in Dydrogesterone group underwent hysterectomy whereas 5.9% women in Norethisterone and 4.7% in Dydrogesterone group opted for therapeutic dilatation and curettage respectively.
Conclusions: Dydrogesterone is as effective as Norethisterone in controlling heavy menstrual bleeding. Dydrogesterone can be considered as a safer and efficacious alternative to Norethisterone given its highly selective nature and the absence of androgenic side effects.
Metrics
References
Sokkary N, Dietrich JE. Management of heavy menstrual bleeding in adolescents. Current Opin Obstet Gynecol. 2012;24(5):275-80. DOI: https://doi.org/10.1097/GCO.0b013e3283562bcb
Dhakane M, Deshmukh S, Raghuwanshi N, Karode H, Wahane. A study of medical management of AUB cases in respect with PALM COEIN classification at tertiary care center. European J Mol Clin Med. 2021;8(4):193-203.
Munro MG, Critchley HOD, Fraser IS. FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143(3):393-408. DOI: https://doi.org/10.1002/ijgo.12666
Jewson M, Purohit P, Lumsden MA. Progesterone and abnormal uterine bleeding/menstrual disorders. Best Pract Res Clin Obstet Gynecol. 2020;69:62-73. DOI: https://doi.org/10.1016/j.bpobgyn.2020.05.004
Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf AL. Treatment of menorrhagia. American Fam Phys. 2007;75(12):1813-9.
Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Women’s Health. 2016;12(1):27-34. DOI: https://doi.org/10.2217/whe.15.100
Sriprasert I, Pakrashi T, Kimble T, Archer DF. Heavy menstrual bleeding diagnosis and medical management. Cont Reprod Med. 2017;2(1):1-8. DOI: https://doi.org/10.1186/s40834-017-0047-4
Wang L, Guan HY, Xia HX, Chen XY, Zhang W. Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding–ovulation dysfunction patients. World J Clin Cases. 2020;8(15):3259. DOI: https://doi.org/10.12998/wjcc.v8.i15.3259
Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 2016;32(2):97-106. DOI: https://doi.org/10.3109/09513590.2015.1121982
Yaaqoub NK. A comparative study between norethisterone progestogens and dydrogesterone in the treatment of dysfunctional uterine bleeding. Am Medical J. 2010;1:23-6. DOI: https://doi.org/10.3844/amjsp.2010.23.26
Yasin A, Afzal M, Aziz U. A comparison between effectiveness of norethisterone and dydrogesterone for treatment of irregular menstrual cycle due to abnormal uterine bleeding of ovulatory and/or endometrial dysfunction in women presenting at gynae outdoor of a tertiary care hospital. PJMHS. 2021;11:2876-8. DOI: https://doi.org/10.53350/pjmhs2115112876
Kader MIA, Karthikeyan V and Sabitha J. A comparative study on efficacy of norethisterone and medroxyprogesterone in the management of dysfunctional uterine bleeding: a prospective observational study. Biosci Biotech Res Asia. 2023;20(2):617-25. DOI: https://doi.org/10.13005/bbra/3115
Sen S, Mandal TK, Dutta A, Mondal H, Khalua T. A comparative study of norethisterone and combined oral contraceptive pill in the treatment of dysfunctional uterine bleeding. Chrismed J Health Res. 2019;6:87-92. DOI: https://doi.org/10.4103/cjhr.cjhr_92_18
Papapanagiotou IK, Charamanta M, Roidi S, Al-Achmar NS, Soldatou A, Michala L. The Use of Norethisterone for the Treatment of Severe Uterine Bleeding in Adolescents: An Audit of Our Experience. J Pediatr Adolesc Gynecol. 2019;32(6):596-9. DOI: https://doi.org/10.1016/j.jpag.2019.09.002
Downloads
Published
How to Cite
Issue
Section
